Related Experiment Videos
[Bronchodilators in chronic obstructive pulmonary disease (COPD)]
Adrian Gillissen1, Roland Buhl, Klaus Friedrich Rabe
1Robert-Koch-Klinik, Klinikum "St. Georg", Leipzig. adrian.gillissen@sanktgeorg.de
Medizinische Klinik (Munich, Germany : 1983)
|May 20, 2005
Summary
Long-acting bronchodilators are recommended for early chronic obstructive pulmonary disease (COPD) treatment. Combining therapies and inhaled corticosteroids in later stages improve lung function and quality of life.
Area of Science:
- Pulmonary Medicine
- Pharmacotherapy
- Clinical Trials
Background:
- Bronchodilators are foundational in managing chronic obstructive pulmonary disease (COPD).
- Choosing optimal bronchodilator therapy is complex due to numerous drug classes, mechanistic differences, and fixed combinations.
- Clinical trial data guides treatment decisions for COPD patients.
Purpose of the Study:
- To review clinical efficacy of various bronchodilator classes in COPD.
- To establish effective disease management objectives.
- To propose an evidence-based treatment algorithm for COPD pharmacotherapy.
Main Methods:
- Review of large, double-blind clinical trials.
- Evaluation of anticholinergic drugs, long- and short-acting beta(2)-agonists, and xanthines.
- Assessment of different application forms and drug combinations.
Main Results:
- Inhalation therapy with long-acting bronchodilators (e.g., tiotropium, formoterol, salmeterol) is proposed for early COPD treatment.
- Combination therapy of anticholinergics and long-acting bronchodilators may offer additive bronchodilatory effects.
- Inhaled corticosteroids are recommended only for stages III and IV COPD.
Conclusions:
- Early treatment algorithms for COPD should prioritize long-acting bronchodilators.
- Pharmacotherapy for COPD requires a comprehensive approach including smoking cessation and supportive care.
- Optimizing bronchodilator selection and combination improves lung function, reduces exacerbations, and enhances quality of life in COPD patients.